Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Yarrow Bioscience Inc (YARW)

46 + Investors. Track Smart Money conviction in YARW. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%

46+

Inst. Holders

Hedge Fund Ownership: YARW

How many hedge funds hold YARW — quarterly history vs. share price
Quarterly hedge fund ownership of YARW vs. share price

Market Analysis: YARW

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: YARW

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Yarrow Bioscience Inc (YARW) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much YARW has moved relative to its sector benchmark (XLV) since the 2026 Q3 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End September 30, 2026 · 50d ago
YARW
-36.9%
XLV
+7.6%

YARW outperformed XLV by -44.5% since September 30, 2026.

Since 13F Filing Date November 14, 2026 · 5d ago
YARW
-21.2%
XLV
-4.1%

Since the filing became public, YARW outperformed XLV by -17.1% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

5 top-rated funds 1 high-conviction
Consensus
3.4
/ 10
breadth
×
Elite
1.6
/ 10
conviction
Hedge Fund Positioning: YARW
46 + Investors

Track Smart Money conviction in YARW. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q3) Prior (2026 Q2) Change
Funds Holding 46 0 100%
13F Shares 9M 0 100%
Total Value $206M $0 100%
New Positions 46 0 +46
Increased Positions 0 0 -
Closed Positions 0 0 -
Reduced Positions 0 0 -
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: YARW

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q3)

46 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in YARW. Verified SEC 13F-HR filings.

Top 25 YARW holders by conviction (% of portfolio weight) — 2026 Q3 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Monashee Investment Management LLC 2.70% 40,000 $901K
2 venBio Partners LLC 2.52% 554,769 $12.5M
3 Spruce Street Capital LP 2.17% 607,382 $13.7M
4 Squadron Capital Management LLC 1.27% 225,000 $5.1M
5 Logos Global Management LP 1.25% 1,026,258 $23.1M
6 Silverarc Capital Management, LLC 0.80% 301,919 $6.8M
7 Bellevue Group AG 0.47% 1,000,000 $22.5M
8 Siren, L.L.C. 0.36% 675,000 $15.2M
9 Soleus Capital Management, L.P. 0.33% 416,993 $9.4M
10 Perceptive Advisors LLC 0.32% 813,098 $18.3M
11 Braidwell LP 0.31% 331,400 $7.5M
12 KVP Capital Advisors, LP 0.18% 10,011 $225K
13 Seven Fleet Capital Management LP 0.18% 40,000 $901K
14 Orbimed Advisors LLC 0.11% 266,306 $6.0M
15 Lynx1 Capital Management LP 0.08% 22,000 $495K
16 Driehaus Capital Management LLC 0.05% 305,000 $6.9M
17 Prelude Capital Management, LLC 0.03% 16,975 $382K
18 Nantahala Capital Management, LLC 0.03% 39,198 $883K
19 Aster Capital Management (DIFC) Ltd 0.03% 3,179 $72K
20 J. Goldman & Co LP 0.03% 55,751 $1.3M
21 Persistent Asset Partners Ltd 0.02% 3,092 $70K
22 Atom Investors LP 0.01% 10,206 $230K
23 Marshall Wace, LLP 0.00% 237,183 $5.3M
24 XTX Topco Ltd 0.00% 12,282 $277K
25 Ameriprise Financial Inc 0.00% 739,538 $16.7M
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Yarrow Bioscience Inc (YARW)

Is it too late to buy Yarrow Bioscience Inc (YARW) following the 2026 Q3 hedge fund 13F filings?

As of today, YARW has moved -21.2% since the 2026 Q3 13F filing date (November 14, 2026), compared to -4.1% for the XLV sector ETF — an outperformance of -17.1%. Since the quarter end (September 30, 2026), YARW has gained -36.9% vs +7.6% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →